Use of AHRi1 (CH-223191) with anti-PD-1 led to delayed tumor progression and prolonged survival in B16IDO and B16TDO tumors models when compared with single agent therapy (Fig. 4e). This evidence concerns the gene PDCD1 and neoplasm.